MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Search

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

518.11 1.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

501.13

Max

518.37

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+35.62% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.7B 12B
Vorige openingsprijs	516.89
Vorige sluitingsprijs	518.11

Nieuwssentiment

By Acuity

30%

70%

111 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 apr 2026, 20:44 UTC

Winsten

Costco Reports 11% Growth in March Sales

8 apr 2026, 23:51 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 apr 2026, 23:51 UTC

Marktinformatie

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 apr 2026, 23:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 apr 2026, 22:56 UTC

Marktinformatie

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 apr 2026, 22:45 UTC

Marktinformatie

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 apr 2026, 22:17 UTC

Marktinformatie

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 apr 2026, 21:52 UTC

Belangrijke Nieuwsgebeurtenissen

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 apr 2026, 21:24 UTC

Winsten

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 apr 2026, 21:01 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

8 apr 2026, 20:43 UTC

Acquisities, Fusies, Overnames

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 apr 2026, 20:43 UTC

Acquisities, Fusies, Overnames

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 apr 2026, 20:43 UTC

Acquisities, Fusies, Overnames

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 apr 2026, 20:42 UTC

Acquisities, Fusies, Overnames

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 apr 2026, 20:42 UTC

Acquisities, Fusies, Overnames

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 apr 2026, 20:42 UTC

Acquisities, Fusies, Overnames

Oracle Responds to TRC Cap Mini-Tender Offer

8 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 apr 2026, 19:44 UTC

Winsten

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 apr 2026, 19:16 UTC

Marktinformatie

Hogs Follow Cutout Prices Lower -- Market Talk

8 apr 2026, 19:02 UTC

Marktinformatie

Global Energy Roundup: Market Talk

8 apr 2026, 19:02 UTC

Marktinformatie

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 apr 2026, 18:58 UTC

Marktinformatie

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 apr 2026, 18:51 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 apr 2026, 18:51 UTC

Marktinformatie

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 apr 2026, 18:14 UTC

Belangrijke Nieuwsgebeurtenissen

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 apr 2026, 18:05 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

35.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 704.88 USD 35.62%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

111 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Andere aandelen uit de sector

MDT

Medtronic PLC

88.75

A

Agilent Technologies Inc

116.89

VEEV

Veeva Systems Inc

166.33

HQY

HealthEquity Inc

81.95

TLRY

Tilray Brands Inc

6.75

Live chat